Netazepide, a Gastrin/CCK2 Receptor Antagonist, Can Eradicate Gastric Neuroendocrine Tumours in Patients with Autoimmune Chronic Atrophic Gastritis

#1339

Introduction: In a two-centre, 12-week, open trial in 16 patients with chronic atrophic gastritis, hypergastrinaemia, multiple gastric NETs, and raised circulating CgA, the gastrin/CCK2 receptor antagonist, netazepide, reduced the tumour number and size, and normalised CgA.

Aim(s): To treat those patients with netazepide for longer, and to identify new biomarkers.

Materials and methods: After mean 14 months off netazepide, 13 patients took it for another 52 weeks. Assessments: gastroscopy; gene transcript expression in corpus biopsies and gastrin-treated CCK2R expressing gastric epithelial (AGSGR) cells in vitro using microarrays and qPCR; and blood CgA and gastrin (p<0.01).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Boyce M

Authors: Boyce M, Moore A, Parsons B, Lloyd K, Sagatun L,

Keywords: Netazepide,